AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11531834 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin 1.25 mg kg(‐1) daily
Number of subjects: 150
Study 11531834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus alone
Number of subjects: 150
Study 11531834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus plus reduced‐dose cyclosporin
Number of subjects: 150
Study 9894177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 293
Study 9894177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 293
Study 9894177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 293
Study 7847746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 4 h sleep regime after 44th‐46th h of sleep deprivation
Number of subjects: 20
Study 7847746 — intervention group
Group type: COMPARATOR
Intervention: Sleep-deprived controls
Number of subjects: 20
Study 3395921 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (Hylorin)
Number of subjects: 14
Study 3395921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% polyvinyl alcohol (Refresh)
Number of subjects: 14
Study 31730369 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Therapy (ABMT)
Number of subjects: 37
Study 31730369 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 37
Study 30246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive screw-retained, metal-ceramic prosthesis in occlusion within 1 week after placement
Number of subjects: 40
Study 30246184 — intervention group
Group type: COMPARATOR
Intervention: Non-occluding provisional acrylic reinforced prosthesis within 24 h of implant placement
Number of subjects: 40
Study 30246184 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive screw-retained, metal-ceramic prosthesis in occlusion
Number of subjects: 40
Study 30246184 — intervention group
Group type: COMPARATOR
Intervention: Non-occluding provisional acrylic reinforced prosthesis
Number of subjects: 40
Study 26620368 — intervention group
Group type: EXPERIMENTAL
Intervention: One course of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 382
Study 26620368 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 382
Study 25630699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 20
Study 23887468 — intervention group
Group type: EXPERIMENTAL
Intervention: melaxen (melatonin IR)
Number of subjects: 45
Study 21384320 — intervention group
Group type: EXPERIMENTAL
Intervention: DBE
Number of subjects: 130
Study 21384320 — intervention group
Group type: COMPARATOR
Intervention: SBE
Number of subjects: 130
Study 18199715 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood levels of 18:1n‐9t
Number of subjects: 14916
Study 18199715 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 18:2t
Number of subjects: 14916
Study 18199715 — intervention group
Group type: EXPERIMENTAL
Intervention: Total trans‐fatty acids
Number of subjects: 14916
Study 18199715 — intervention group
Group type: COMPARATOR
Intervention: None of the trans fats examined
Number of subjects: 14916
Study 16814131 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with continuous transdermal estradiol patch (36 microg/day) plus cyclic oral medroxyprogesterone acetate (MPA; 2.5 mg/day for 12 days) for 12 months
Number of subjects: 38
Study 16814131 — intervention group
Group type: COMPARATOR
Intervention: Oral hormone replacement therapy (HRT) with continuous oral conjugated equine estrogens (CEE; 0.625 mg/day) plus cyclic oral MPA (2.5 mg/day for 12 days) for 12 months
Number of subjects: 38
Study 12904807 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual
Number of subjects: 0
Study 12904807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11345684 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling supplemented by physiotherapy
Number of subjects: 40
Study 11345684 — intervention group
Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 40
Study 9377880 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1000 mg every 8 hrs)
Number of subjects: 211
Study 9377880 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2000 mg) plus Tobramycin (1 mg/kg every 8 hrs)
Number of subjects: 211
Study 1539460 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at health centre 1
Number of subjects: 0
Study 1539460 — intervention group
Group type: COMPARATOR
Intervention: Vaccination at health centre 2
Number of subjects: 0
Study 2861873 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 65
Study 2861873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 65
Study 2861873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31399500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 157
Study 31399500 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 157
Study 27988804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm
Number of subjects: 82
Study 27988804 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 82
Study 27988804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm + Desmopressin
Number of subjects: 82
Study 27988804 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study 27988804 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 82
Study 25595404 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow device (3-mm or 4-mm)
Number of subjects: 80
Study 25595404 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 80
Study 25595404 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow device (4-mm)
Number of subjects: 80
Study 25595404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Optiflow and control)
Number of subjects: 80
Study 25595404 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow device
Number of subjects: 80
Study 24099621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 73
Study 21792770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 95
Study 21792770 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted surgery (LAS)
Number of subjects: 95
Study 19154827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity session of 24 repeated right-side slips
Number of subjects: 46
Study 19154827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity initial session of a single slip with high-frequency ancillary training
Number of subjects: 46
Study 19154827 — intervention group
Group type: COMPARATOR
Intervention: Single-slip exposure without ancillary sessions
Number of subjects: 46
Study 17283312 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (500 mg twice daily)
Number of subjects: 579
Study 17283312 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (200 mg twice daily)
Number of subjects: 579
Study 17283312 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 579
Study 17283312 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine
Number of subjects: 579
Study 12524670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise program (3 half-hour sessions per week)
Number of subjects: 60
Study 12524670 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (4,186 to 6,279 kJ.d(‐1))
Number of subjects: 60
Study 12524670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vigorous exercise and energy restriction
Number of subjects: 60
Study 12524670 — intervention group
Group type: COMPARATOR
Intervention: Control light exercise program
Number of subjects: 60
Study 10563033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 129
Study 10563033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with Nicorette gum
Number of subjects: 129
Study 10563033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with cue exposure
Number of subjects: 129
Study 10563033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with cue exposure and Nicorette gum
Number of subjects: 129
Study 8899261 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical device in cervical canal (group I)
Number of subjects: 298
Study 8899261 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical device in uterine cavity (group II)
Number of subjects: 298
Study 1812498 — intervention group
Group type: EXPERIMENTAL
Intervention: maroxepine 2.5 mg
Number of subjects: 15
Study 1812498 — intervention group
Group type: EXPERIMENTAL
Intervention: maroxepine 5.0 mg
Number of subjects: 15
Study 1812498 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine 75 mg
Number of subjects: 15
Study 1812498 — intervention group
Group type: COMPARATOR
Intervention: imipramine 75 mg
Number of subjects: 15
Study 1812498 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 7107115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 14
Study 4025191 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef fat (BF)
Number of subjects: 19
Study 4025191 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (CO)
Number of subjects: 19
Study 4025191 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (SO)
Number of subjects: 19
Study 29174166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-simulation orientation
Number of subjects: 24
Study 29174166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-simulation orientation)
Number of subjects: 24
Study 27464018 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 α‐hydroxyprogesterone caproate (17OHP‐C)
Number of subjects: 459
Study 27464018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 25280414 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) intake as percentage of daily energy (median 5.3%)
Number of subjects: 118
Study 25280414 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) intake as percentage of daily energy (median 8.2%)
Number of subjects: 118
Study 22148989 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intensive meditation/emotion regulation training
Number of subjects: 82
Study 22148989 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study 20075928 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan therapy for 6 months
Number of subjects: 219
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) levels in follicular fluids
Number of subjects: 132
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL-2) levels in follicular fluids
Number of subjects: 132
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN-gamma) levels in follicular fluids
Number of subjects: 132
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 levels in follicular fluids
Number of subjects: 132
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL5 levels in follicular fluids
Number of subjects: 132
Study 18503053 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF levels in follicular fluids
Number of subjects: 132
Study 15816795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day titrated to 60 mg/day over 2 weeks)
Number of subjects: 30
Study 15816795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (continued)
Number of subjects: 30
Study 15816795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched from mirtazapine)
Number of subjects: 30
Study 12767103 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron with dexamethasone
Number of subjects: 360
Study 12767103 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin
Number of subjects: 360
Study 12767103 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 360
Study 12767103 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 360
Study 10777431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 0
Study 10777431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8842885 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (6 sessions of thermal training and 6 sessions of electromyographic training over a 6 week period)
Number of subjects: 150
Study 8842885 — intervention group
Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 150
Study 1625515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg p.o. at 09.00 h)
Number of subjects: 20
Study 1625515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6328684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine
Number of subjects: 50
Study 6328684 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 50
Study 30182773 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing + standard advice (MI + SA)
Number of subjects: 37
Study 30182773 — intervention group
Group type: COMPARATOR
Intervention: Standard advice (SA)
Number of subjects: 37
Study 29415180 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 212
Study 27572327 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone hexacetonide (TH)
Number of subjects: 70
Study 27572327 — intervention group
Group type: COMPARATOR
Intervention: 8 mg dexamethasone (DEX)
Number of subjects: 70
Study 25202955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1,000 mg/d on the day of operation and on the first 3 postoperative days)
Number of subjects: 60
Study 25202955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22704112 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ubiquinol daily for 26 weeks
Number of subjects: 228
Study 22704112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 20600480 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ-50300 (conventional dose: 1.0x10(8) plaque-forming units/mL)
Number of subjects: 123
Study 20600480 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ-50300 (low dose: 1.0x10(7) plaque-forming units/mL)
Number of subjects: 123
Study 20600480 — intervention group
Group type: COMPARATOR
Intervention: CJ-50300 (conventional dose)
Number of subjects: 123
Study 19186344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needle
Number of subjects: 80
Study 19186344 — intervention group
Group type: COMPARATOR
Intervention: Sham needle
Number of subjects: 80
Study 16438875 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-PEI
Number of subjects: 86
Study 16438875 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 86
Study 16438875 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-PEI (Group A, diameter <= 3.0 cm)
Number of subjects: 86
Study 16438875 — intervention group
Group type: COMPARATOR
Intervention: RFA (Group A, diameter <= 3.0 cm)
Number of subjects: 86
Study 16438875 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-PEI (Group B, diameter = 3.1-5.0 cm)
Number of subjects: 86
Study 16438875 — intervention group
Group type: COMPARATOR
Intervention: RFA (Group B, diameter = 3.1-5.0 cm)
Number of subjects: 86
Study 11876581 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 487
Study 11876581 — intervention group
Group type: COMPARATOR
Intervention: Drug counseling
Number of subjects: 487
Study 11876581 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher psychiatric severity
Number of subjects: 487
Study 11876581 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of full treatment
Number of subjects: 487
Study 11876581 — intervention group
Group type: EXPERIMENTAL
Intervention: Living situation (with partner vs alone)
Number of subjects: 487
Study 10655905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng ml‐1)
Number of subjects: 9
Study 10655905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 ng ml‐1)
Number of subjects: 9
Study 10655905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0 ng ml‐1)
Number of subjects: 9
Study 10655905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng ml‐1) and (0.6 ng ml‐1)
Number of subjects: 9
Study 10655905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 9
Study 8952581 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 0
Study 8952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 0
Study 1849571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation, palatable form, duration up to three weeks
Number of subjects: 0
Study 1849571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7140435 — intervention group
Group type: EXPERIMENTAL
Intervention: Special 3-week training program including discussions about deafness, communication techniques, and free-play interactions with deaf children.
Number of subjects: 0
Study 7140435 — intervention group
Group type: EXPERIMENTAL
Intervention: Special 3-week training program
Number of subjects: 0
Study 7140435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31907056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sang-qi granules (SQG)
Number of subjects: 300
Study 31907056 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 300
Study 31907056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sang-qi granules (SQG) and Losartan
Number of subjects: 300
Study 30511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 42
Study 30511788 — intervention group
Group type: COMPARATOR
Intervention: Standardised Talking Control (TC)
Number of subjects: 42
Study 28733314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter valve treatment for 30 min/d for 4 weeks
Number of subjects: 17
Study 28733314 — intervention group
Group type: COMPARATOR
Intervention: Control (flutter-sham)
Number of subjects: 17
Study 25554556 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable ECG lead wires
Number of subjects: 1611
Study 25554556 — intervention group
Group type: COMPARATOR
Intervention: Reusable ECG lead wires
Number of subjects: 1611
Study 23856626 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-2 (fully channel-by-channel programmable device with automatic noise management and multichannel directional microphone)
Number of subjects: 11
Study 23856626 — intervention group
Group type: COMPARATOR
Intervention: SP-1 (multichannel device with omnidirectional microphone)
Number of subjects: 11
Study 23856626 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-2
Number of subjects: 11
Study 23856626 — intervention group
Group type: COMPARATOR
Intervention: SP-1 and SP-2
Number of subjects: 11
Study 22118754 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g fructose and 33.3 g erythritol
Number of subjects: 37
Study 22118754 — intervention group
Group type: COMPARATOR
Intervention: 50 g fructose and 50 g glucose
Number of subjects: 37
Study 22118754 — intervention group
Group type: COMPARATOR
Intervention: 50 g fructose alone
Number of subjects: 37
Study 19233534 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips used twice daily for 30 minutes over a 2-week period
Number of subjects: 148
Study 16951900 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive training program (manual passive treatment)
Number of subjects: 18
Study 16951900 — intervention group
Group type: COMPARATOR
Intervention: Mechanical active passive training
Number of subjects: 18
Study 15582061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound examinations (5 studies between 18 and 38 weeks' gestation)
Number of subjects: 2714
Study 15582061 — intervention group
Group type: COMPARATOR
Intervention: Single prenatal ultrasound examination (1 study at 18 weeks' gestation)
Number of subjects: 2714
Study 15582061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound examinations (5 studies)
Number of subjects: 2714
Study 15582061 — intervention group
Group type: COMPARATOR
Intervention: Single prenatal ultrasound examination (1 study)
Number of subjects: 2714
Study 11745871 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 404
Study 11745871 — intervention group
Group type: COMPARATOR
Intervention: D-COMP
Number of subjects: 404
Study 9292609 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator (Breathe Right)
Number of subjects: 53
Study 7678358 — intervention group
Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 44
Study 7678358 — intervention group
Group type: EXPERIMENTAL
Intervention: UW-mod solution
Number of subjects: 44
Study 7678358 — intervention group
Group type: COMPARATOR
Intervention: Euro-Collins solution
Number of subjects: 44
Study 3539363 — intervention group
Group type: EXPERIMENTAL
Intervention: First generation soft-tipped catheters
Number of subjects: 413
Study 3539363 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheters
Number of subjects: 413
Study 3539363 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation soft-tipped catheters
Number of subjects: 413
Study 31827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 15045
Study 31827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 15045
Study 31827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C level
Number of subjects: 15045
Study 31827007 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one component of MetS
Number of subjects: 15045